Last update June 10, 2018
Very High Risk
An analgesic derived from pyrazolone, inhibitor of prostaglandin synthesis by inhibiting cyclooxygenase.
Administered orally and rectally.
Since the last update date we have not found published data on its excretion in breastmilk.
Severe hemolytic anemia has been reported in a newborn whose mother was taking it (Frei 1985).
Since 1989, it has been withdrawn from sale in many countries for having caused medullary aplasia, Lyell's syndrome and other serious side effects (Onakpoya 2018).
It is marketed in multiple preparations that combine caffeine, codeine, atropine and anti-inflammatory drugs. In general, drug combinations are not recommended and even less so during breastfeeding.
Known alternatives which are safer during breastfeeding are preferred, especially during the neonatal period and in the case of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM